Clinical trial · Interventional
Preoperative Chemoradiotherapy Combined With Nimotuzumab for Cervical Cancer
Preoperative Concurrent Chemoradiotherapy Combined With Nimotuzumab Injection for Locally Advanced Cervical Cancer: a Phase II Study
NCT01938105CI-TRIAL-00012280unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine the feasibility and efficacy of preoperative nimotuzumab injection combined with concurrent chemoradiotherapy for initially inoperable, locally advanced cervical cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Locally Advanced Cervical Cancer | Malignant Cervical Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Nimotuzumab+chemoradiotherapy | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Nimotuzumab+chemoradiotherapy
- interventionNames
- Other: Nimotuzumab+chemoradiotherapy
Primary outcomes (2)
- measure
- Treatment related toxicities
- timeFrame
- at 1 year
- description
- Acute and chronic toxicities.
- measure
- Tumor response after preoperative treatment
- timeFrame
- assessed at 4-5 weeks after the completion of preoperative treatment
Secondary outcomes (2)
- measure
- Progression-free survival
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically or cytologically proven squamous cell cervical cancer * Stages IB2-IIIB according to FIGO Staging System * Age:18-75 * ECOG\<2 * Normal bone marrow function * Initial assessed and considered not candidates for operation * Signed study-specific consent form Exclusion Criteria: * Pregnant or lactating women * Patients with other malignancies * Patients who received radiotherapy or chemotherapy previously * Presence of uncontrolled life-threatening illness * Allergy to platinum or monoclonal antibody
References
Publications (0)
Data not yet available
No reference posted for this study.